newsfilter
← Earnings
Earnings Releases·

Generate Biomedicines — Third Quarter 2026 Earnings Summary

  • Revenue declined to $4.2 million from $9.6 million in the prior year period due to nearing completion of Amgen and Novartis research obligations, while R&D expenses rose to $82.3 million from $62.2 million driven by GB-0895 Phase 3 SOLAIRIA trials.
  • Net loss widened to $87.7 million from $60.0 million in the prior year; cash and marketable securities decreased to $404.2 million as of September 30, 2026, from $457.4 million at June 30, 2026.
  • Management expects current liquidity plus a $30.0 million upfront payment from Zealand Pharma received in October 2026 to fund operations through the first half of 2028, though additional capital will be required for long-term needs.
  • Strategic progress includes the October 2026 Zealand Pharma partnership for obesity/metabolic diseases with up to $1.2 billion in potential milestones, alongside Phase 1 enrollment for GB-4362 and first patient dosing for GB-5267 in ovarian cancer.
Company
GENERATE BIOMEDICINES INC
Sector
Healthcare
Industry
Biotechnology